Introduction The recent findings from the DESTINY-Breast06 Phase III trial signify a potential shift in the treatment landscape for HR-positive,…
Browsing: Phase 3
By: Neal Shore, MD Date: October 25, 2023 In the abstract describing the EMBARK Phase 3 trial, Dr. Neal Shore…
The recent approval by the Food and Drug Administration (FDA) of mirvetuximab soravtansine-gynx (Elahere) marks a significant advancement in the…
Mark Schoenberg, MD- UrologyGenitourinary (GU) CancerBladder Cancer-The Montefiore Medical Center and The Albert Einstein College of Medicine at UroGen Pharma…
Does Atezolizumab SBRT Improve Progression-Free Survival In NSCLC? Atezolizumab is an immune checkpoint inhibitor that targets PDL-1. It has been…